Qun-Hua Wu

Metabolic reprogramming-related drug resistance in osteosarcoma: from molecular mechanisms to therapeutic translation

Background Osteosarcoma remains the most prevalent primary malignant bone tumor in adolescents and young adults. For patients with localized disease, 5-year overall survival reaches 60%–70%; however, for those with metastatic or recurrent disease, 5-year survival remains stagnant at approximately 20%, and chemoresistan...